Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan

Type 2 Diabetes Mellitus Clinical Trial

Official title:

A Long-term, Open-label Extension Study to Investigate the Long-term Safety of SYR-322 When Used in Combination With α-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01263509
• Other study ID #: SYR-322/OCT-003
• Secondary ID: U1111-1118-3992
• Status: Completed
• Phase: Phase 2/Phase 3
• First received: December 17, 2010
• Last updated: February 1, 2012
• Start date: June 2007
• Est. completion date: October 2008

Study information

• Verified date: February 2012
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Ministry of Health, Labor and Welfare
• Study type: Interventional

Clinical Trial Summary

The purpose of this study was to evaluate the long-term safety and efficacy of alogliptin and an α-glucosidase inhibitor administered once daily (QD) or three times daily (TID) for 40 consecutive weeks in participants who completed a phase 2/3 α-glucosidase inhibitor add on study.

Description:

Both insulin hyposecretion and insulin-resistance are considered to be involved in the development of type 2 diabetes mellitus.

Takeda is developing SYR-322 (alogliptin) for the improvement of glycemic control in patients with type 2 diabetes mellitus. Alogliptin is an inhibitor of the dipeptidyl peptidase IV (DPP-IV) enzyme. DPP-IV is thought to be primarily responsible for the degradation of 2 peptide hormones released in response to nutrient ingestion. It is expected that inhibition of DPP-IV will improve glycemic control in patients with type 2 diabetes.

"To evaluate the long-term safety and efficacy of alogliptin and an α-glucosidase inhibitor, this extension study was administered for 40 consecutive weeks (52 weeks from the start of treatment in the phase 2 dose-ranging study) to participants who completed a phase 2/3 α-glucosidase inhibitor add on study 322/CCT-003 (NCT01263483).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 179
• Est. completion date: October 2008
• Est. primary completion date: October 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 33 Years to 85 Years

Eligibility

Inclusion Criteria:

• Had completed the phase 2 dose-ranging study (i.e., the subject had completed the study visit at Week 12).

Exclusion Criteria:

• Had clinical manifestations of hepatic impairment (e.g., an aspartate aminotransferase or alanine aminotransferase value 2.5 times or more of the upper reference limit at Week 8 of treatment in the phase 2 dose-ranging study).

• Had clinical manifestations of renal impairment (e.g., a creatinine value of 2 mg/dL or more at Week 8 of treatment in the phase 2 dose-ranging study).

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type 2 Diabetes Mellitus

Intervention

Drug:
• Alogliptin and voglibose
Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
• Alogliptin and voglibose
Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Takeda

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Adverse Events.	A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug and within 30 days after receiving the last dose of study drug. A TEAE may also be a pre-treatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug, which increases in intensity after the start of dosing. Adverse events data with onset occurring more than 30 days after last dose of study drug (AE start date - last dose date >30) will be listed, but not included in the summary tables below.	52 Weeks.	Yes
Secondary	Change From Baseline in Glycosylated Hemoglobin (Week 8).	The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline.	Baseline and Week 8.	No
Secondary	Change From Baseline in Glycosylated Hemoglobin (Week 12).	The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and glycosylated hemoglobin collected at baseline.	Baseline and Week 12.	No
Secondary	Change From Baseline in Glycosylated Hemoglobin (Week 16).	The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 16 and glycosylated hemoglobin collected at baseline.	Baseline and Week 16.	No
Secondary	Change From Baseline in Glycosylated Hemoglobin (Week 20).	The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 20 and glycosylated hemoglobin collected at baseline.	Baseline and Week 20.	No
Secondary	Change From Baseline in Glycosylated Hemoglobin (Week 24).	The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 and glycosylated hemoglobin collected at baseline.	Baseline and Week 24.	No
Secondary	Change From Baseline in Glycosylated Hemoglobin (Week 28).	The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 28 and glycosylated hemoglobin collected at baseline.	Baseline and Week 28.	No
Secondary	Change From Baseline in Glycosylated Hemoglobin (Week 32).	The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 32 and glycosylated hemoglobin collected at baseline.	Baseline and Week 32.	No
Secondary	Change From Baseline in Glycosylated Hemoglobin (Week 36).	The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 36 and glycosylated hemoglobin collected at baseline.	Baseline and Week 36.	No
Secondary	Change From Baseline in Glycosylated Hemoglobin (Week 40).	The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 40 and glycosylated hemoglobin collected at baseline.	Baseline and Week 40.	No
Secondary	Change From Baseline in Glycosylated Hemoglobin (Week 44).	The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 44 and glycosylated hemoglobin collected at baseline.	Baseline and Week 44.	No
Secondary	Change From Baseline in Glycosylated Hemoglobin (Week 48).	The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 48 and glycosylated hemoglobin collected at baseline.	Baseline and Week 48.	No
Secondary	Change From Baseline in Glycosylated Hemoglobin (Week 52).	The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 52 and glycosylated hemoglobin collected at baseline.	Baseline and Week 52.	No
Secondary	Change From Baseline in Glycosylated Hemoglobin (Final Visit).	The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 52 or final visit and glycosylated hemoglobin collected at baseline.	Baseline and Final Visit (up to Week 52).	No
Secondary	Change From Baseline in Fasting Plasma Glucose (Week 8).	The change between the value of fasting plasma glucose collected at week 8 and fasting plasma glucose collected at baseline.	Baseline and Week 8.	No
Secondary	Change From Baseline in Fasting Plasma Glucose (Week 12).	The change between the value of fasting plasma glucose collected at week 12 and fasting plasma glucose collected at baseline.	Baseline and Week 12.	No
Secondary	Change From Baseline in Fasting Plasma Glucose (Week 16).	The change between the value of fasting plasma glucose collected at week 16 and fasting plasma glucose collected at baseline.	Baseline and Week 16.	No
Secondary	Change From Baseline in Fasting Plasma Glucose (Week 20).	The change between the value of fasting plasma glucose collected at week 20 and fasting plasma glucose collected at baseline.	Baseline and Week 20.	No
Secondary	Change From Baseline in Fasting Plasma Glucose (Week 24).	The change between the value of fasting plasma glucose collected at week 24 and fasting plasma glucose collected at baseline.	Baseline and Week 24.	No
Secondary	Change From Baseline in Fasting Plasma Glucose (Week 28).	The change between the value of fasting plasma glucose collected at week 28 and fasting plasma glucose collected at baseline.	Baseline and Week 28.	No
Secondary	Change From Baseline in Fasting Plasma Glucose (Week 32).	The change between the value of fasting plasma glucose collected at week 32 and fasting plasma glucose collected at baseline.	Baseline and Week 32.	No
Secondary	Change From Baseline in Fasting Plasma Glucose (Week 36).	The change between the value of fasting plasma glucose collected at week 36 and fasting plasma glucose collected at baseline.	Baseline and Week 36.	No
Secondary	Change From Baseline in Fasting Plasma Glucose (Week 40).	The change between the value of fasting plasma glucose collected at week 40 and fasting plasma glucose collected at baseline.	Baseline and Week 40.	No
Secondary	Change From Baseline in Fasting Plasma Glucose (Week 44).	The change between the value of fasting plasma glucose collected at week 44 and fasting plasma glucose collected at baseline.	Baseline and Week 44.	No
Secondary	Change From Baseline in Fasting Plasma Glucose (Week 48).	The change between the value of fasting plasma glucose collected at week 48 and fasting plasma glucose collected at baseline.	Baseline and Week 48.	No
Secondary	Change From Baseline in Fasting Plasma Glucose (Week 52).	The change between the value of fasting plasma glucose collected at week 52 and fasting plasma glucose collected at baseline.	Baseline and Week 52.	No
Secondary	Change From Baseline in Fasting Plasma Glucose (Final Visit).	The change between the value of fasting plasma glucose collected at week 52 or final visit and fasting plasma glucose collected at baseline.	Baseline and Final Visit (up to Week 52).	No
Secondary	Change From Baseline in Fasting C-peptide (Week 8).	The change between the value of fasting C-peptide collected at week 8 and fasting C-peptide collected at baseline.	Baseline and Week 8.	No
Secondary	Change From Baseline in Fasting C-peptide (Week 12).	The change between the value of fasting C-peptide collected at week 12 and fasting C-peptide collected at baseline.	Baseline and Week 12.	No
Secondary	Change From Baseline in Fasting C-peptide (Week 16).	The change between the value of fasting C-peptide collected at week 16 and fasting C-peptide collected at baseline.	Baseline and Week 16.	No
Secondary	Change From Baseline in Fasting C-peptide (Week 20).	The change between the value of fasting C-peptide collected at week 20 and fasting C-peptide collected at baseline.	Baseline and Week 20.	No
Secondary	Change From Baseline in Fasting C-peptide (Week 24).	The change between the value of fasting C-peptide collected at week 24 and fasting C-peptide collected at baseline.	Baseline and Week 24.	No
Secondary	Change From Baseline in Fasting C-peptide (Week 28).	The change between the value of fasting C-peptide collected at week 28 and fasting C-peptide collected at baseline.	Baseline and Week 28.	No
Secondary	Change From Baseline in Fasting C-peptide (Week 32).	The change between the value of fasting C-peptide collected at week 32 and fasting C-peptide collected at baseline.	Baseline and Week 32.	No
Secondary	Change From Baseline in Fasting C-peptide (Week 36).	The change between the value of fasting C-peptide collected at week 36 and fasting C-peptide collected at baseline.	Baseline and Week 36.	No
Secondary	Change From Baseline in Fasting C-peptide (Week 40).	The change between the value of fasting C-peptide collected at week 40 and fasting C-peptide collected at baseline.	Baseline and Week 40.	No
Secondary	Change From Baseline in Fasting C-peptide (Week 44).	The change between the value of fasting C-peptide collected at week 44 and fasting C-peptide collected at baseline.	Baseline and Week 44.	No
Secondary	Change From Baseline in Fasting C-peptide (Week 48).	The change between the value of fasting C-peptide collected at week 48 and fasting C-peptide collected at baseline.	Baseline and Week 48.	No
Secondary	Change From Baseline in Fasting C-peptide (Week 52).	The change between the value of fasting C-peptide collected at week 52 and fasting C-peptide collected at baseline.	Baseline and Week 52.	No
Secondary	Change From Baseline in Fasting C-peptide (Final Visit).	The change between the value of fasting C-peptide collected at week 52 or final visit and fasting C-peptide collected at baseline.	Baseline and Final Visit (up to Week 52).	No
Secondary	Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value) (Week 12).	The change between the value of blood glucose collected at week 12 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal.	Baseline and Week 12.	No
Secondary	Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value) (Week 24).	The change between the value of blood glucose collected at week 24 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal.	Baseline and Week 24.	No
Secondary	Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value) (Week 52).	The change between the value of blood glucose collected at week 52 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal.	Baseline and Week 52.	No
Secondary	Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value) (Final Visit).	The change between the value of blood glucose collected at week 52 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal.	Baseline and Final Visit (up to Week 52).	No
Secondary	Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (AUC (0-2)) (Week 12).	The change between the value of blood glucose collected at week 12 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal.	Baseline and Week 12.	No
Secondary	Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (AUC (0-2)) (Week 24).	The change between the value of blood glucose collected at week 24 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal.	Baseline and Week 24.	No
Secondary	Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (AUC (0-2)) (Week 52).	The change between the value of blood glucose collected at week 52 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal.	Baseline and Week 52.	No
Secondary	Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (AUC (0-2)) (Final Visit).	The change between the value of blood glucose collected at week 52 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal.	Baseline and Final Visit (up to Week 52).	No
Secondary	Change From Baseline in Insulin Measured by Meal Tolerance Testing (AUC(0-2)) (Week 12).	The change between the value of insulin collected at week 12 and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal.	Baseline and Week 12.	No
Secondary	Change From Baseline in Insulin Measured by Meal Tolerance Testing (AUC(0-2)) (Week 24).	The change between the value of insulin collected at week 24 and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal.	Baseline and Week 24.	No
Secondary	Change From Baseline in Insulin Measured by Meal Tolerance Testing (AUC(0-2)) (Week 52).	The change between the value of insulin collected at week 52 and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal.	Baseline and Week 52.	No
Secondary	Change From Baseline in Insulin Measured by Meal Tolerance Testing (AUC(0-2)) (Final Visit).	The change between the value of insulin collected at week 52 or final visit and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal.	Baseline and Final Visit (up to Week 52).	No
Secondary	Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2)) (Week 12).	The change between the value of C-peptide collected at week 12 and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal.	Baseline and Week 12.	No
Secondary	Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2)) (Week 24).	The change between the value of C-peptide collected at week 24 and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal.	Baseline and Week 24.	No
Secondary	Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2)) (Week 52).	The change between the value of C-peptide collected at week 52 and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal.	Baseline and Week 52.	No
Secondary	Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2)) (Final Visit).	The change between the value of C-peptide collected at week 52 or final visit and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal.	Baseline and Final Visit (up to Week 52).	No
Secondary	Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)) (Week 12).	The change between the value of glucagons collected at week 12 and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal.	Baseline and Week 12.	No
Secondary	Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)) (Week 24).	The change between the value of glucagons collected at week 24 and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal.	Baseline and Week 24.	No
Secondary	Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)) (Week 52).	The change between the value of glucagons collected at week 52 and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal.	Baseline and Week 52.	No
Secondary	Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)) (Final Visit).	The change between the value of glucagons collected at week 52 or final visit and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal.	Baseline and Final Visit (up to Week 52).	No